MA41790B1 - Dérivé de morphinane - Google Patents

Dérivé de morphinane

Info

Publication number
MA41790B1
MA41790B1 MA41790A MA41790A MA41790B1 MA 41790 B1 MA41790 B1 MA 41790B1 MA 41790 A MA41790 A MA 41790A MA 41790 A MA41790 A MA 41790A MA 41790 B1 MA41790 B1 MA 41790B1
Authority
MA
Morocco
Prior art keywords
represent hydrogen
ring
atoms
carbon atoms
carbon atom
Prior art date
Application number
MA41790A
Other languages
English (en)
Other versions
MA41790A (fr
Inventor
Hiroshi Nagase
Hideaki Fujii
Akiyoshi Saitoh
Eriko Nakata
Masaaki Hirose
Isao Ooi
Kohei Hayashida
Original Assignee
Nippon Chemiphar Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56919074&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA41790(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nippon Chemiphar Co filed Critical Nippon Chemiphar Co
Publication of MA41790A publication Critical patent/MA41790A/fr
Publication of MA41790B1 publication Critical patent/MA41790B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Dérivé de morphinane représenté par la formule générale (i) suivante : (où r1 représente l'hydrogène, un alkyle en c1-10, un cycloalkylalkyle où le fragment cycloalkyle a 3 à 6 atomes de carbone, et le fragment alkylène a 1 à 5 atomes de carbone, etc.,r2 représente cycle hétérocyclique contenant 1 à 4 hétéroatomes choisis parmi n, o et s et au moins un atome de carbone en tant qu'atomes constituant le cycle, contenant au moins un ensemble d'atomes constituant le cycle adjacents liés par une double liaison, et en outre substitué par au moins un groupe oxo,y se lie à un atome de carbone en tant qu'atome constituant le cycle de r2, r3, r4 et r5 représentent l'hydrogène ; hydroxy, etc., r6a et r6bre représentent l'hydrogène, etc., r7 et r8 représentent l'hydrogène, etc., r9 et r10, qui sont identiques ou différents, représentent l'hydrogène, etc.,x représente o ou ch2, ety représente c(=o)),un tautomère ou stéréoisomère du composé, ou un sel pharmaceutiquement acceptable de celui-ci, ou un solvate de celui-ci est utilisé comme anxiolytique médicament, antidépresseur, etc
MA41790A 2015-03-17 2016-03-17 Dérivé de morphinane MA41790B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015054079 2015-03-17
PCT/JP2016/058475 WO2016148232A1 (fr) 2015-03-17 2016-03-17 Dérivé de morphinane

Publications (2)

Publication Number Publication Date
MA41790A MA41790A (fr) 2021-06-02
MA41790B1 true MA41790B1 (fr) 2022-02-28

Family

ID=56919074

Family Applications (1)

Application Number Title Priority Date Filing Date
MA41790A MA41790B1 (fr) 2015-03-17 2016-03-17 Dérivé de morphinane

Country Status (23)

Country Link
US (5) US10442802B2 (fr)
EP (2) EP3272750B1 (fr)
JP (5) JP6692345B2 (fr)
KR (2) KR102813010B1 (fr)
CN (3) CN113292558A (fr)
AU (2) AU2016234222C1 (fr)
BR (1) BR112017019805B1 (fr)
CA (1) CA2979023C (fr)
CY (1) CY1124908T1 (fr)
DK (1) DK3272750T3 (fr)
ES (1) ES2904511T3 (fr)
HU (1) HUE057266T2 (fr)
IL (1) IL254473B (fr)
MA (1) MA41790B1 (fr)
MX (2) MX2021008741A (fr)
MY (1) MY197742A (fr)
PH (1) PH12017501655B1 (fr)
PL (1) PL3272750T3 (fr)
RU (1) RU2762567C2 (fr)
SG (2) SG11201707427TA (fr)
TW (2) TWI775723B (fr)
WO (1) WO2016148232A1 (fr)
ZA (1) ZA201706882B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2762567C2 (ru) * 2015-03-17 2021-12-21 Ниппон Кемифар Ко., Лтд. Производное морфинана
JPWO2018030382A1 (ja) 2016-08-09 2019-06-13 日本ケミファ株式会社 モルヒナン誘導体
JP6840155B6 (ja) * 2016-09-16 2025-06-17 日本ケミファ株式会社 モルヒナン誘導体のオピオイドδ受容体アゴニスト関連疾患の治療のための使用
JP7283711B2 (ja) * 2016-10-03 2023-05-30 学校法人星薬科大学 モルヒナン誘導体を含む医薬組成物及びその鎮痛剤への使用
KR102979778B1 (ko) 2019-07-19 2026-06-18 닛뽕 케미파 가부시키가이샤 모르피난 유도체의 제조 방법
KR20220035378A (ko) 2019-07-19 2022-03-22 닛뽕 케미파 가부시키가이샤 페놀 유도체의 제조 방법
EP4206203A4 (fr) 2020-08-28 2024-12-11 Nippon Chemiphar Co., Ltd. Procédé de préparation d'un dérivé de morphinane à chaîne principale formée d'éther diarylique utilisant un nouveau catalyseur au cuivre
WO2022181763A1 (fr) * 2021-02-26 2022-09-01 学校法人東京理科大学 Composition pharmaceutique pour le traitement ou la prévention de troubles liés au stress
CN116997360A (zh) * 2021-02-26 2023-11-03 学校法人东京理科大学 应激相关障碍的治疗或预防用医药组合物
TW202547487A (zh) * 2024-03-18 2025-12-16 學校法人東京理科大學 失樂症的治療或預防用醫藥組成物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005231995A (ja) 1999-12-22 2005-09-02 Meiji Seika Kaisha Ltd オピオイドδ受容体アゴニスト/アンタゴニストとして有用なスピロ化合物
DE10161963A1 (de) 2001-12-17 2003-07-03 Johannes Schuetz 6-Aminomorphinanderivate, Herstellungsverfahren dafür und deren Verwendung
CL2004000754A1 (es) 2003-04-11 2005-02-25 Janssen Pharmaceutica Nv Uso de compuestos derivados de 4-fenil-4-(1h-imidazol-2-il)piperidina, como agonistas delta-opioides no peptidicos, para preparar un medicamento util en prevenir o tratar trastornos del sistema nervioso central.
WO2006107254A1 (fr) 2005-04-04 2006-10-12 Astrazeneca Ab Nouveaux diazaspiroalcanes et leur application au traitement de maladies faisant intervenir ccr8
JPWO2008001859A1 (ja) 2006-06-30 2009-11-26 学校法人北里研究所 オピオイドδ受容体アゴニスト
JP2010538094A (ja) 2007-09-06 2010-12-09 アレイ バイオファーマ、インコーポレイテッド チロシンキナーゼ阻害剤としてのピラゾロピリジン類
AU2010313392B2 (en) 2009-10-30 2015-07-09 Janssen Pharmaceutica Nv Pyrazines as delta opioid receptor modulators
WO2011090935A1 (fr) 2010-01-19 2011-07-28 Merck Sharp & Dohme Corp. Composés pyrazolo[1,5-a]pyrimidines en tant qu'inhibiteurs de mtor
US8987293B2 (en) 2010-12-23 2015-03-24 Phoenix Pharmalabs, Inc. Morphinans useful as analgesics
JP2014073964A (ja) 2011-01-28 2014-04-24 Kitasato Institute モルヒナン誘導体
DK2774926T3 (en) 2011-09-09 2017-05-15 The Kitasato Inst morphinan
WO2014021273A1 (fr) * 2012-07-30 2014-02-06 学校法人北里研究所 Dérivés morphinane
US8937084B2 (en) 2012-12-14 2015-01-20 Purdue Pharma L.P. Nitrogen containing morphinan derivatives and the use thereof
EP2966074B1 (fr) 2013-03-08 2018-07-25 The Kitasato Institute Dérivé de morphinane
RU2762567C2 (ru) * 2015-03-17 2021-12-21 Ниппон Кемифар Ко., Лтд. Производное морфинана
JP6840155B6 (ja) 2016-09-16 2025-06-17 日本ケミファ株式会社 モルヒナン誘導体のオピオイドδ受容体アゴニスト関連疾患の治療のための使用

Also Published As

Publication number Publication date
MA41790A (fr) 2021-06-02
US20210040094A1 (en) 2021-02-11
EP3974430A1 (fr) 2022-03-30
KR20230104767A (ko) 2023-07-10
TW202244044A (zh) 2022-11-16
CN113292559B (zh) 2024-04-02
US11643411B2 (en) 2023-05-09
TW201638089A (zh) 2016-11-01
BR112017019805A2 (pt) 2018-05-29
CN107614500B (zh) 2021-06-15
TWI778933B (zh) 2022-09-21
KR102551969B1 (ko) 2023-07-05
SG10201907667RA (en) 2019-09-27
MX2017011824A (es) 2018-04-20
AU2016234222B2 (en) 2020-08-27
CN113292558A (zh) 2021-08-24
MY197742A (en) 2023-07-12
SG11201707427TA (en) 2017-10-30
CA2979023A1 (fr) 2016-09-22
MX2021008741A (es) 2022-11-01
US20260159517A1 (en) 2026-06-11
MX384744B (es) 2025-03-14
HUE057266T2 (hu) 2022-05-28
US20230159530A1 (en) 2023-05-25
JP7375076B2 (ja) 2023-11-07
CY1124908T1 (el) 2023-01-05
AU2020270503B2 (en) 2023-02-02
AU2016234222A1 (en) 2017-10-26
PL3272750T3 (pl) 2022-03-07
JP2020117533A (ja) 2020-08-06
PH12017501655A1 (en) 2018-03-12
JP2022081656A (ja) 2022-05-31
AU2020270503C1 (en) 2023-08-10
WO2016148232A1 (fr) 2016-09-22
JP2025131782A (ja) 2025-09-09
ES2904511T3 (es) 2022-04-05
JPWO2016148232A1 (ja) 2018-03-08
AU2020270503A1 (en) 2020-12-17
TWI775723B (zh) 2022-09-01
ZA201706882B (en) 2022-02-23
US10442802B2 (en) 2019-10-15
AU2016234222C1 (en) 2021-02-11
IL254473B (en) 2022-05-01
US20200079775A1 (en) 2020-03-12
IL254473A0 (en) 2017-11-30
RU2017134286A (ru) 2019-04-05
US20180057493A1 (en) 2018-03-01
KR20180002616A (ko) 2018-01-08
KR102813010B1 (ko) 2025-05-26
EP3272750A1 (fr) 2018-01-24
JP2024010098A (ja) 2024-01-23
CA2979023C (fr) 2023-09-26
RU2017134286A3 (fr) 2019-04-19
EP3272750A4 (fr) 2018-08-08
AU2020270503B9 (en) 2023-10-12
PH12017501655B1 (en) 2022-07-22
CN107614500A (zh) 2018-01-19
EP3272750B1 (fr) 2021-11-03
JP6692345B2 (ja) 2020-05-13
AU2020270503C9 (en) 2024-02-29
BR112017019805B1 (pt) 2023-01-31
US10995092B2 (en) 2021-05-04
NZ735939A (en) 2024-09-27
DK3272750T3 (en) 2022-01-03
HK1249900A1 (en) 2018-11-16
CN113292559A (zh) 2021-08-24
RU2762567C2 (ru) 2021-12-21

Similar Documents

Publication Publication Date Title
MX2020011501A (es) Compuestos novedosos.
PE20040164A1 (es) Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas
PE20251288A1 (es) Compuestos heterociclicos como inmunomoduladores
PH12022551014A1 (en) Substituted tricyclic compounds
UY38297A (es) Compuestos derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona, composiciones, métodos y usos de los mismos
MY197742A (en) Morphinan derivative
SV2017005384A (es) Compuestos aminopirimidinilo
MA28024A1 (fr) Derives de (thio) carbamoyl-cyclohexane utilises en tant qu'antagonistes des recepteurs d3/d2
MA32164B1 (fr) Derive heterocyclique fusionne et son utilisation
AR056043A1 (es) Agonistas de receptores adrenergicos alfa2c funcionalmente selectivos
AR107321A1 (es) Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos
AR094272A1 (es) Compuestos de diona ciclica activos como herbicidas, o derivados de los mismos, sustituidos por un fenilo que tiene un sustituyente que contiene alquinilo
AR116906A1 (es) Derivados de heteroarilo bicíclico
AR116713A1 (es) COMPUESTOS DE IMIDAZOLINDIONA COMO REGULADORES DE CANALES Kv3
MA53370B1 (fr) Procédé et intermédiaires pour la préparation de bilastine
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
JOP20220082A1 (ar) مشتقات 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4
EA202192760A1 (ru) Трициклические соединения
MA50093B1 (fr) Composé pentacyclique
AR116428A1 (es) Compuestos de 6-fluoro-2-metilbenzo[d]tiazol-5-ilo
MA41885B1 (fr) Mélange d'additifs
JOP20220084A1 (ar) مشتقات 5-أوكسا- 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4
MX2022005415A (es) Compuesto de imidazolidinona, metodo de preparacion del mismo y uso del mismo.
JOP20240119A1 (ar) مشتقات نافثيريدينون لمعالجة مرض أو اضطراب
MA41975B1 (fr) Derives d'aminohydrothiazine fusionnee contenant du tetrahydrofurane utiles dans le traitement de la maladie d'alzheimer